Radioligand therapy
Radioligand therapy is a targeted nuclear-medicine cancer treatment that delivers radiation directly to tumor cells through receptor-binding molecules.
History
Covers 180 months, 2011-10 to 2026-09 · Peaked in 2026-06; now at 91% of peak
Last 24 months
What to build with it
Monthly searches: 3,600 · 90-day growth: +16.2% · 12-month growth: +293.2%
The history spans 180 months; current interest is 91% of the historical peak.
Run a "Radioligand therapy" comparison and review site that only answers "which one is worth it" — affiliate revenue, much lighter than building software.
This is seasonal demand that peaks in September; a product launched later barely catches any volume.
Metric
| Metric | Value |
|---|---|
| Estimated monthly searches | 3,600 |
| 90-day growth | +16.2% |
| 12-month growth | +293.2% |
| Listed for | 1 months |
| Carrier | Website / App / SaaS |
| Form | Content site / database |
| Opportunity type | Flat |
| Stage | Long-term growth |
| Window | Just listed |
| Seasonality | 62% |
| Volatility | 19% |
Seasonality
Score breakdown
Opportunity score：90.2 / 100
Related opportunities
Frequently asked questions
What is the monthly search volume for Radioligand therapy
About 3,600 searches per month (estimate); +16.2% over the last 90 days.
Is Radioligand therapy better for a website or a product
It mainly comes down to the carrier and the form. Digital product: delivered online, so acquisition cost and monetisation matter most.
Search interest comes from Google Trends. Monthly volume is an estimate converted with standard keyword-tool methodology, while growth and scores are computed by us from the historical curve. About the data